Skip to main content
. Author manuscript; available in PMC: 2021 Apr 29.
Published in final edited form as: Gene. 2018 Feb 20;655:1–12. doi: 10.1016/j.gene.2018.02.048

Figure 6: Analgesic activity of the REV-ERB agonist SR9009 in a model of osteoarthritis induced pain.

Figure 6:

Fig.6A (single intrathecal injection; n=13) & Fig.6B (multiple intraarticular injections; n=7–8) where, mechanical hyperalgesia was measured using von Frey filament test. In OA mice, the paw withdrawal threshold (PWT) was elevated in the SR9009 treated group vs. the vehicle group. For Figs. C-I (intraarticular injection; n=7–8): (6C) Heat hyperalgesia was measured using hot-plate test. The paw thermal threshold (PTT) was elevated in the SR9009 treated group at 12 weeks (n = 7–8 per group). But, locomotor behavioral results (6D-6E) were not significant between groups. However, histological results (6F-6I) for cartilage protective and degenerative changes were shown in Fig. 6G (sham), Fig. 6H (PMM) and Fig. 6I (SR9009 treated group of mice), and histological scoring data (Fig. 6F) was better in the SR9009 treated group compared to vehicle treated OA mice. Values are mean±SEM.